Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma--review.
- Author:
Ling-Hao LI
1
;
Hui-Min LI
Author Information
1. Department of Hematology, The Second People Hospital of Yunnan Province, Kunming 650021, China.
- Publication Type:Journal Article
- MeSH:
Angiogenesis Inhibitors;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
Apoptosis;
drug effects;
Arsenicals;
therapeutic use;
Humans;
Lymphoma;
drug therapy;
Oxides;
therapeutic use
- From:
Journal of Experimental Hematology
2007;15(6):1335-1339
- CountryChina
- Language:Chinese
-
Abstract:
Arsenic trioxide has been used to treat lymphoma experimentally since it was used to treat acute promyelocytic leukemia successfully. Massive works in this field have been done throughout the world. It was found that arsenic trioxide exerted an anti-lymphomatic effect via many pathways, and many substances could increase or reduce this effect. Arsenic trioxide can be used to treat relapsed and refractory lymphomas resistant to other chemotherapies with some therapeutic effects and limited side effects, which indicates that arsenic trioxide is a new potential drug for lymphoma. This article is an overview about these foundational and clinical studies.
